# Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/rfa-ns-26-030-genomic-and-biologic-therapies-for-adrd-u01-clinical/  
Official notice: https://www.grants.gov/search-results-detail/361287

> National Institutes of Health plans to offer grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expects to make about 3 awards worth $6.0 million in total. It is a forecast: the notice is expected around July 1, 2026, with applications due around November 10, 2026.

| Field | Value |
|---|---|
| Opportunity number | RFA-NS-26-030 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | expected November 10, 2026 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 3 |
| Total funding | $6.0 million |
| Cost sharing | not required |
| Assistance Listings | 93.853 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

## What the grant funds

The National Institutes of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects proposing the optimization and translational development of genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD). Breakthroughs in genomic and biologic therapies are creating new opportunities to treat, prevent, and potentially modify the course of dementias; however, progress is limited by challenges in delivery, safety, manufacturability, and readiness for clinical testing. This program is intended to support projects across the translational pipeline, from optimization through IND development and early clinical evaluation, for genomic and biologic therapeutic candidates with compelling preclinical evidence. Eligible projects may include activities to refine therapeutic design and manufacturability; establish pharmacology, toxicology, biodistribution, and in vivo efficacy; to generate the full body of data required to support regulatory interactions and IND submissions, and, when appropriate, first-in-human (FIH) clinical studies. The program is aligned with priorities from the ADRD Summits, including acceleration of disease-modifying therapeutic development in frontotemporal degeneration (FTD), Lewy body dementia (LBD), and vascular contributions to cognitive impairment and dementia (VCID). Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

## Questions people ask

### Who can apply for Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)?

National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)?

Expected deadline November 10, 2026. Confirm the date and time in the official notice on Grants.gov.

### How much funding is available?

About $6.0 million in total across about 3 awards.